BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 24611490)

  • 1. A new role for the nonpathogenic nonsynonymous single-nucleotide polymorphisms of acetylcholinesterase in the treatment of Alzheimer's disease: a computational study.
    Saravanaraman P; Chinnadurai RK; Boopathy R
    J Comput Biol; 2014 Aug; 21(8):632-47. PubMed ID: 24611490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and evaluation of 7H-thiazolo-[3,2-b]-1,2,4-triazin-7-one derivatives as dual binding site acetylcholinesterase inhibitors.
    Liu S; Shang R; Shi L; Zhou R; He J; Wan DC
    Chem Biol Drug Des; 2014 Aug; 84(2):169-74. PubMed ID: 24890706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease.
    Zhou A; Hu J; Wang L; Zhong G; Pan J; Wu Z; Hui A
    J Mol Model; 2015 Oct; 21(10):277. PubMed ID: 26438408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Novel Acetylcholinesterase Inhibitors as Potential Candidates for the Treatment of Alzheimer's Disease.
    Son M; Park C; Rampogu S; Zeb A; Lee KW
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revealing the mechanistic pathway of cholinergic inhibition of Alzheimer's disease by donepezil: a metadynamics simulation study.
    Ghosh S; Jana K; Ganguly B
    Phys Chem Chem Phys; 2019 Jul; 21(25):13578-13589. PubMed ID: 31173012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cooperative hydrogen bonds and mobility of the non-aromatic ring as selectivity determinants for human acetylcholinesterase to similar anti-Alzheimer's galantaminics: a computational study.
    Rocha REO; Lima LHF
    J Biomol Struct Dyn; 2019 Apr; 37(7):1843-1856. PubMed ID: 29697300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, design and biological evaluation of novel highly potent tacrine congeners for the treatment of Alzheimer's disease.
    Hamulakova S; Janovec L; Hrabinova M; Kristian P; Kuca K; Banasova M; Imrich J
    Eur J Med Chem; 2012 Sep; 55():23-31. PubMed ID: 22818849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational approach to suggest a new multi-target-directed ligand as a potential medication for Alzheimer's disease.
    Eslami M; Nezafat N; Negahdaripour M; Ghasemi Y
    J Biomol Struct Dyn; 2019 Nov; 37(18):4825-4839. PubMed ID: 30689517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease.
    Gurung AB; Aguan K; Mitra S; Bhattacharjee A
    J Biomol Struct Dyn; 2017 Jun; 35(8):1729-1742. PubMed ID: 27410776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, biological evaluation and molecular modeling study of novel tacrine-carbazole hybrids as potential multifunctional agents for the treatment of Alzheimer's disease.
    Thiratmatrakul S; Yenjai C; Waiwut P; Vajragupta O; Reubroycharoen P; Tohda M; Boonyarat C
    Eur J Med Chem; 2014 Mar; 75():21-30. PubMed ID: 24508831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxime-dipeptides as anticholinesterase, reactivator of phosphonylated-serine of AChE catalytic triad: probing the mechanistic insight by MM-GBSA, dynamics simulations and DFT analysis.
    Chadha N; Tiwari AK; Kumar V; Lal S; Milton MD; Mishra AK
    J Biomol Struct Dyn; 2015; 33(5):978-90. PubMed ID: 24805972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of ligand-based pharmacophore modeling and docking approach to find novel acetylcholinesterase inhibitors for treating Alzheimer's.
    Dhanjal JK; Sharma S; Grover A; Das A
    Biomed Pharmacother; 2015 Apr; 71():146-52. PubMed ID: 25960230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential acetylcholinesterase inhibitors: molecular docking, molecular dynamics, and in silico prediction.
    Kiametis AS; Silva MA; Romeiro LA; Martins JB; Gargano R
    J Mol Model; 2017 Feb; 23(2):67. PubMed ID: 28185116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining in silico and in vitro approaches to evaluate the acetylcholinesterase inhibitory profile of some commercially available flavonoids in the management of Alzheimer's disease.
    Kuppusamy A; Arumugam M; George S
    Int J Biol Macromol; 2017 Feb; 95():199-203. PubMed ID: 27871793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico analyses of acetylcholinesterase (AChE) and its genetic variants in interaction with the anti-Alzheimer drug Rivastigmine.
    Pereira GRC; Gonçalves LM; Abrahim-Vieira BA; De Mesquita JF
    J Cell Biochem; 2022 Jul; 123(7):1259-1277. PubMed ID: 35644025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and evaluation of flavonoid derivatives as potential multifunctional acetylcholinesterase inhibitors against Alzheimer's disease.
    Li RS; Wang XB; Hu XJ; Kong LY
    Bioorg Med Chem Lett; 2013 May; 23(9):2636-41. PubMed ID: 23511019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of potential inhibitor against human acetylcholinesterase: a molecular docking and molecular dynamics investigation.
    Singh SP; Gupta D
    Comput Biol Chem; 2017 Jun; 68():224-230. PubMed ID: 28432980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel tacrine analogs as potential cholinesterase inhibitors in Alzheimer's disease.
    El-Malah A; Gedawy EM; Kassab AE; Salam RM
    Arch Pharm (Weinheim); 2014 Feb; 347(2):96-103. PubMed ID: 24343873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantifying ligand-receptor interactions for gorge-spanning acetylcholinesterase inhibitors for the treatment of Alzheimer's disease.
    Martis EA; Chandarana RC; Shaikh MS; Ambre PK; D'Souza JS; Iyer KR; Coutinho EC; Nandan SR; Pissurlenkar RR
    J Biomol Struct Dyn; 2015; 33(5):1107-25. PubMed ID: 24905476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates.
    Camps P; Formosa X; Galdeano C; Gómez T; Muñoz-Torrero D; Ramírez L; Viayna E; Gómez E; Isambert N; Lavilla R; Badia A; Clos MV; Bartolini M; Mancini F; Andrisano V; Bidon-Chanal A; Huertas O; Dafni T; Luque FJ
    Chem Biol Interact; 2010 Sep; 187(1-3):411-5. PubMed ID: 20167211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.